Adrenoleukodystrophy – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline Review, H2 2020’, provides an overview of the Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)

– The report reviews pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) therapeutics and enlists all their major and minor projects

– The report assesses Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Applied Genetic Technologies Corp

Ashvattha Therapeutics LLC

bluebird bio Inc

Magenta Therapeutics Inc

MedDay SA

Minoryx Therapeutics sl

NeuroVia Inc

Orpheris Inc

Poxel SA

Recursion Pharmaceuticals Inc

SwanBio Therapeutics Ltd

Viking Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Adrenoleukodystrophy- Overview

Adrenoleukodystrophy- Therapeutics Development

Adrenoleukodystrophy- Therapeutics Assessment

Adrenoleukodystrophy- Companies Involved in Therapeutics Development

Adrenoleukodystrophy- Drug Profiles

Adrenoleukodystrophy- Dormant Projects

Adrenoleukodystrophy- Discontinued Products

Adrenoleukodystrophy- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Applied Genetic Technologies Corp, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Ashvattha Therapeutics LLC, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by bluebird bio Inc, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Magenta Therapeutics Inc, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by MedDay SA, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Minoryx Therapeutics sl, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by NeuroVia Inc, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Orpheris Inc, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Poxel SA, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Recursion Pharmaceuticals Inc, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by SwanBio Therapeutics Ltd, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Pipeline by Viking Therapeutics Inc, H2 2020

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) – Dormant Projects, H2 2020

List of Figures

List of Figures

Number of Products under Development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports